Clinical trial NCT00159744: 3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008)
Official title: A Phase III, Randomized, Placebo-Controlled, Double-Blind Trial Evaluating the Safety and Efficacy of Sublingual Asenapine vs. Olanzapine and Placebo in In-Patients With an Acute Manic Episode Clinical Trial Protocol 7501004 (Secondary Title: ARES)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Bipolar Disorder
Lead sponsor: Organon and Co
Sponsor class: INDUSTRY
Collaborators: name: Pfizer
First posted: 2005-09-12
Enrollment: 488
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Bipolar disorder is characterized by mood swings that range from high (manic) to low (depressed) states. Sometimes, symptoms of both depression and mania are present (mixed episodes). Asenapine is an investigational medication for the treatment of manic or mixed episodes of bipolar disorder. This is a 3-week study that will test the safety and efficacy of this medication. Patients will receive either asenapine, olanzapine (a medication that is already approved for the treatment of bipolar mania), or placebo (no active medication). Patients will be required to stay in the hospital for at least the first seven days of treatment. Patients that complete the 3 week study may be eligible to continue in extension studies for an additional 9 (study A7501006) to 49 (study A7501007) weeks.


Eligibility criteria: Inclusion Criteria:

* Have a DSMIV diagnosis of bipolar I disorder, current episode manic or mixed.

Exclusion Criteria:

* Patients with unstable medical conditions or clinically significant laboratory abnormalities or patients who are rapid cyclers (ie. have had 4 or more (including current) mood episodes in the past 12 months); have any other psychiatric disorder other than bipolar I disorder as a primary diagnosis.

Primary outcomes:
measure: Changes in bipolar manic or mixed symptoms reflected in the scores on the YMRS (Young Mania Rating Scale)
timeFrame: The YMRS was administered at screening, baseline, Day 2, 4, 7, 14 and 21
Secondary outcomes:
measure: Ratings on the Clinical Global Impression scale in which severity and improvement of mania, depression, and overall bipolar state are rated.
timeFrame: The CGI assessment at days 1,7 and endpoint (day 21 or the time of the last assessment).
measure: The PANSS (Positive and Negative Symptom Scale) was used to assess psychotic symptoms
timeFrame: The PANSS was administered at Days 1, 7 and 21(or the time of the last assessment).
measure: The MADRS (Montgomery Asberg Depression Rating Scale) was used to assess depressive symptoms
timeFrame: The MADRS was administered on Days 1, 7 and 21(or at the time of the last assessment).l
measure: The Readiness for Discharge Questionaire (RDQ) was administered to characterize the subject's readiness for discharge. The investigator was to make the decision about discharging the subject.
timeFrame: The RDQ was administered on Day 1, 2, 4, 7 , 14 and 21 (or at the time of the last assessment)
measure: CogState, cognition battery, was used to assess changes in cognition
timeFrame: Cog State was administered at screening, Day 1 (baseline) and Days 7, 14, 21 (or endpoint).
measure: SF (short form)-36 and TSQM (Treatment Satisfaction Questionnaire for Medication) -- 2 measures of Quality of Life were administered.
timeFrame: The SF Health Survey was administered at Day 1 and Day 21 or endpoint. The TSMQ was administered at Day 21 or endpoint..
measure: The SARS (Simpson Angus Rating Scale); the AIMS (Involuntary Movement Scale and the BARS (Barnes Akathisia Scale) were used to assess extrapyramidal symptoms
timeFrame: The SARS, AIMS and BARS assessments were administered at Days 1, 7 and 21 or endpoint.
measure: Concomitant medication use was recorded
timeFrame: Concomitant medication use was recorded whenever it occurred
measure: Physical examination, laboratory and electrocardiogram findings and weight/abdominal girth and vital signs were recorded.
timeFrame: Physical exam, ECG, laboratory and weight were recorded at screening and Day 21 or endpoint. Laboratory work was also done at baseline.
measure: Adverse events (AEs)
timeFrame: AEs were recorded whenever they occurred..
measure: Pharmacokinetic analysis was done to determine the level of the drug in the blood
timeFrame: Pk samples were taken at Day 1, 7, 14 and 21 (or endpoint).
Other outcomes:
Locations:
Study officials:
References:
citation: McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord. 2010 Apr;122(1-2):27-38. doi: 10.1016/j.jad.2009.12.028. Epub 2010 Jan 22.
citation: Suppes T, Eberhard J, Lemming O, Young AH, McIntyre RS. Anxiety, irritability, and agitation as indicators of bipolar mania with depressive symptoms: a post hoc analysis of two clinical trials. Int J Bipolar Disord. 2017 Nov 6;5(1):36. doi: 10.1186/s40345-017-0103-7.
citation: Michalak EE, Guiraud-Diawara A, Sapin C. Asenapine treatment and health-related quality of life in patients experiencing bipolar I disorder with mixed episodes: post-hoc analyses of pivotal trials. Curr Med Res Opin. 2014 Apr;30(4):711-8. doi: 10.1185/03007995.2013.874988. Epub 2014 Jan 10.
citation: Szegedi A, Zhao J, McIntyre RS. Early improvement as a predictor of acute treatment outcome in manic or mixed episodes in bipolar-1 disorder: a pooled, post hoc analysis from the asenapine development program. J Affect Disord. 2013 Sep 25;150(3):745-52. doi: 10.1016/j.jad.2013.01.024. Epub 2013 Mar 6.